The FDA’s review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines. In February 2026, U.S. labeling for Saxenda, Wegovy and Zepbound removed the warning after that review [3] [5] [6] [7].
What regulatory reviews found
The FDA’s trial review did not find increased suicidal ideation or behavior versus placebo. Its Sentinel insurance-claims analysis also found no increased risk of intentional self-harm among people with type 2 diabetes starting a GLP-1 medicine compared with those starting an SGLT2 inhibitor. The FDA continues to collect suspected side-effect reports through MedWatch [3].
In April 2024, the European Medicines Agency’s safety committee concluded that the available evidence did not support a causal link for dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide. The review did not include tirzepatide [4].
What the European reports measured
Our guide to FDA adverse event reports explains why reports are useful for finding possible safety signals. EudraVigilance is a separate reporting system. In the European study, 42,941 reports met the selection criteria for type 2 diabetes, weight management or both [1].
In the weight-management-only subgroup, 225 reports described suspected suicide- or self-injury-related events: 37 naming liraglutide, 141 naming semaglutide and 47 naming tirzepatide. Compared with tirzepatide, the reporting odds ratio was 2.69 for semaglutide (95% confidence interval 1.91–3.83) and 2.54 for liraglutide (1.60–4.01) [1].
What patient records can show
A Swedish national cohort studied adults with depression or anxiety and looked at a broader measure of worsening mental illness. That measure included several outcomes beyond suicidal thoughts. The findings cannot establish that a GLP-1 medicine prevents self-harm [2].
If you develop new or worsening thoughts of suicide or self-harm, seek medical help right away. If you are in immediate danger, call your local emergency services.